Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster, +11

The Lancet

HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy +8

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad, +12

The Lancet

HepatologyHepatitis CPlacebo-controlled Phase 3Viral HepatitisAntiviral Drug Development +7

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Michael Fried, Gregory J. Dore, Robert Flisiak, +14

Hepatology

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Xavier Forns, Eric Lawitz, Stefan Zeuzem, +13

Gastroenterology

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

Stefan Zeuzem, Thomas Berg, Edward Gane, +15

Gastroenterology

Viral PersistenceViral HepatitisAntiviral TherapyHepatitisVirology +7

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor

Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, +11

Journal of Medicinal Chemistry

Hepatitis C VirusImmunologyPharmacotherapyImmunotherapeuticsAntiviral Drug +18

<i>In Vitro</i> Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

Oliver Lenz, Thierry Verbinnen, Tse‐I Lin, +16

Antimicrobial Agents and Chemotherapy

Molecular VirologyViral HepatitisPathogenesisImmunologyHcv Genotype 1 +12

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

Tse‐I Lin, Oliver Lenz, Gregory Fanning, +12

Antimicrobial Agents and Chemotherapy

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Paul Y. Kwo, Norman Gitlin, Ronald Nahass, +15

Hepatology

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Eric Lawitz, Gary Matusow, Edwin DeJesus, +17

Hepatology